• Explore /
  • Poster
  • / A study of pembrolizumab (pembro) in combination with Y90 radioembolization in patients (pts) with poor prognosis hepatocellular carcinoma (HCC) with preserved liver function.

A study of pembrolizumab (pembro) in combination with Y90 radioembolization in patients (pts) with poor prognosis hepatocellular carcinoma (HCC) with preserved liver function.

Abstract Poster

Authors

Autumn McRee

Autumn Jackson McRee

UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC

Autumn Jackson McRee , Paul R. Helft , William Proctor Harris , Hanna Kelly Sanoff , Matthew Johnson , Menggang Yu , Bert O'Neil

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Track

Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT03099564

DOI

10.1200/JCO.2022.40.4_suppl.422

Abstract #

422

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Ashwin Somasundaram

First Author: Masatoshi Kudo

First Author: Jiayu Duan

First Author: Timothy J. Brown